<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01614574</url>
  </required_header>
  <id_info>
    <org_study_id>HGT-GCB-087</org_study_id>
    <nct_id>NCT01614574</nct_id>
  </id_info>
  <brief_title>Study of Velaglucerase Alfa Enzyme Replacement Therapy in Japanese Patients With Gaucher Disease</brief_title>
  <official_title>A Multicenter, Open-Label Study of Velaglucerase Alfa Enzyme Replacement Therapy in Japanese Patients With Gaucher Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gaucher disease is an inherited deficiency of the lysosomal enzyme glucocerebrosidase (GCB)
      that leads to progressive accumulation of glucocerebroside within macrophages and subsequent
      tissue and organ damage; typically of the liver, spleen, bone marrow, and brain. The disease
      has been classified into 3 clinical subtypes based on the presence or absence of neurological
      symptoms and severity of neurological disease. Type 1 Gaucher disease affects an estimated
      30,000 persons worldwide and is the most common. Type 1 Gaucher disease does not involve the
      central nervous system. Patients with type 2 Gaucher disease present with acute neurological
      deterioration, which leads to early death. Those with type 3 disease typically display a more
      sub-acute neurological course, with later onset and slower progression.

      The primary objective of this study is to evaluate the safety of every other week dosing of
      velaglucerase alfa in Japanese patients with Gaucher disease.

      Velaglucerase alfa has been developed and approved as an enzyme replacement therapy for Type
      1 Gaucher disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gaucher disease is an inherited deficiency of the lysosomal enzyme glucocerebrosidase (GCB)
      that leads to progressive accumulation of glucocerebroside within macrophages and subsequent
      tissue and organ damage; typically of the liver, spleen, bone marrow, and brain.

      Gaucher disease has been designated in the list of Specified Rare and Intractable Diseases by
      Specified Disease Treatment Research Program of Ministry of Health, Labor and Welfare (MHLW)
      as one of &quot;lysosomal storage diseases&quot; since 2001. Gaucher disease is also designated in the
      Medical Aid Program for Specified Categories of Chronic Pediatric Diseases.

      The prevalence of mutations and the phenotype of patients with Gaucher disease in Japan
      differs from that in non-Japanese populations. Some patients with type 1 Gaucher disease in
      Japan have more severe and progressive disease compared to non-Japanese patients and the
      disease is characterized by an earlier onset of symptoms.

      Velaglucerase alfa, a highly-purified form of the naturally occurring enzyme
      glucocerebrosidase, has been developed as an enzyme replacement therapy for Gaucher disease
      for the symptoms (anemia, thrombocytopenia, hepatomegaly, splenomegaly, and bone
      manifestation).

      The primary objective of this study is to evaluate the safety of every other week dosing of
      velaglucerase alfa in Japanese patients (naive or previously treated with imiglucerase) 2
      years of age and older with Gaucher disease.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Severe Adverse Events (SAE)</measure>
    <time_frame>Baseline to week 51</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Treatment Emergent Adverse Events (TEAE)</measure>
    <time_frame>Baseline to week 51</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Development of Anti-velaglucerase Alfa Antibody</measure>
    <time_frame>Baseline to week51</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Infusion- Related Adverse Events</measure>
    <time_frame>Baseline to week 51</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With Concomitant Medication</measure>
    <time_frame>Baseline to week 51</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hemoglobin Concentration</measure>
    <time_frame>Baseline to week 51</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Platelet Count</measure>
    <time_frame>Baseline to week 51</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Liver Volume, Normalized to Body Weight</measure>
    <time_frame>Baseline to week 51</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Spleen Volume, Normalized to Body Weight</measure>
    <time_frame>Baseline to week 51</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma Chitotriosidase Levels</measure>
    <time_frame>Baseline to week 51</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CCL18 Levels</measure>
    <time_frame>Baseline to week 51</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Gaucher Disease</condition>
  <arm_group>
    <arm_group_label>Investigational</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>velaglucerase alfa</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>velaglucerase alfa</intervention_name>
    <description>60 U/kg every other week intravenous infusion</description>
    <arm_group_label>Investigational</arm_group_label>
    <other_name>VPRIV</other_name>
    <other_name>Gene activated human glucocerebrosidase</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient has a documented diagnosis of Gaucher disease

          -  The patient is at least 2 years of age

          -  Female patients of child bearing potential must agree to use a medically acceptable
             method of contraception at all times during the study

          -  The patient, the patient's parent(s) or legal guardian(s) has provided written
             informed consent that has been approved by the Institutional Review Board/Independent
             Ethics Committee (IRB/IEC)

          -  The patient must be sufficiently cooperative to participate in this clinical study as
             judged by the Investigator

        Patients who are switched from imiglucerase ERT must meet the following additional
        criteria:

          -  Received treatment with imiglucerase for a minimum of 12 consecutive months

          -  Meet predefined limits for hemoglobin concentration and platelet counts

        Patients na√Øve to treatment for Gaucher disease must meet the following additional
        criteria:

          -  Not received treatment for Gaucher disease (investigational or approved products)
             within 12 months prior to study entry

          -  Have Gaucher disease related anemia and at least one of the following: moderate
             splenomegaly or, Gaucher disease-related thrombocytopenia or Gaucher disease-related
             enlarged liver

        Exclusion Criteria:

          -  Treatment with any investigational drug or device within the 30 days prior to study
             entry (time of informed consent); such use during the study is not permitted

          -  Positive for hepatitis B or hepatitis C.

          -  Non-Gaucher disease related anemia

          -  The patient, patient's parent(s), or patient's legal guardian(s) is/are unable to
             understand the nature, scope, and possible consequences of the study

          -  Significant comorbidity, as determined by the Investigator that might affect study
             data or confound the study results

          -  The patient is unable to comply with the protocol or is unlikely to complete the
             study, as determined by the Investigator

          -  The patient has experienced a severe (grade 3 or higher) infusion-related
             hypersensitivity reaction (anaphylactic or anaphylactoid reaction) to any ERT
             (approved or investigational)

          -  Currently receiving red blood cell growth factor, (eg, erythropoietin) or chronic
             systemic corticosteroids in the last 6 months

          -  Patient has had a splenectomy or the patient has an active, clinically significant
             spleen infarction within 12 months of screening

          -  Patient has worsening bone necrosis within 12 months of screening

          -  The patient is pregnant or lactating.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bjorn Mellgard, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Shire</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hamamatsu University School of Medicine</name>
      <address>
        <city>Hamamatsu</city>
        <state>Shizuoka</state>
        <zip>431-3192</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Jikei University School of Medicine</name>
      <address>
        <city>Minato-ku</city>
        <state>Toyko</state>
        <zip>105-8461</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka City University Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>545-0051</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 6, 2012</study_first_submitted>
  <study_first_submitted_qc>June 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2012</study_first_posted>
  <results_first_submitted>March 25, 2014</results_first_submitted>
  <results_first_submitted_qc>July 8, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 4, 2014</results_first_posted>
  <last_update_submitted>July 8, 2014</last_update_submitted>
  <last_update_submitted_qc>July 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gaucher Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>VPRIV¬Æ (15-60 U/kg)</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>VPRIV¬Æ (15-60 U/kg)</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20" spread="10.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>JAPAN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemoglobin Concentration</title>
          <units>(g/dL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.77" spread="0.954"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Platelet Count</title>
          <units>(x 10`{super 9}/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="182.9" spread="32.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Normalized liver volume</title>
          <units>(% of Body Weight)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.92" spread="0.342"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Normalized spleen volume</title>
          <units>(% of Body Weight)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.39" spread="0.067"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Plasma chitotriosidase</title>
          <units>(nmol/mL/h)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1243.7" spread="344.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CCL18 levels</title>
          <units>(ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="134.8" spread="132.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Severe Adverse Events (SAE)</title>
        <time_frame>Baseline to week 51</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VPRIV¬Æ (15-60 U/kg)</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Severe Adverse Events (SAE)</title>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Treatment Emergent Adverse Events (TEAE)</title>
        <time_frame>Baseline to week 51</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VPRIV¬Æ (15-60 U/kg)</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Treatment Emergent Adverse Events (TEAE)</title>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Development of Anti-velaglucerase Alfa Antibody</title>
        <time_frame>Baseline to week51</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VPRIV¬Æ (15-60 U/kg)</title>
          </group>
        </group_list>
        <measure>
          <title>Development of Anti-velaglucerase Alfa Antibody</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Positive (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Positive (Week 51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative (Week 51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Infusion- Related Adverse Events</title>
        <time_frame>Baseline to week 51</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VPRIV¬Æ (15-60 U/kg)</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Infusion- Related Adverse Events</title>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Concomitant Medication</title>
        <time_frame>Baseline to week 51</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VPRIV¬Æ (15-60 U/kg)</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Concomitant Medication</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hemoglobin Concentration</title>
        <time_frame>Baseline to week 51</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VPRIV¬Æ (15-60 U/kg)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hemoglobin Concentration</title>
          <units>(g/dL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.729"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Platelet Count</title>
        <time_frame>Baseline to week 51</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VPRIV¬Æ (15-60 U/kg)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Platelet Count</title>
          <units>(x 10`{super 9}/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8" spread="35.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Liver Volume, Normalized to Body Weight</title>
        <time_frame>Baseline to week 51</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VPRIV¬Æ (15-60 U/kg)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Liver Volume, Normalized to Body Weight</title>
          <units>(% of Body Weight)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Spleen Volume, Normalized to Body Weight</title>
        <time_frame>Baseline to week 51</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VPRIV¬Æ (15-60 U/kg)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Spleen Volume, Normalized to Body Weight</title>
          <units>(% of Body Weight)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.39" spread="0.067"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Plasma Chitotriosidase Levels</title>
        <time_frame>Baseline to week 51</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VPRIV¬Æ (15-60 U/kg)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma Chitotriosidase Levels</title>
          <units>(nmol/mL/h)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-47.3" spread="64.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CCL18 Levels</title>
        <time_frame>Baseline to week 51</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VPRIV¬Æ (15-60 U/kg)</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CCL18 Levels</title>
          <units>(ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" spread="10.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>VPRIV¬Æ (15-60 U/kg)</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>RETINAL DETACHMENT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>RETINOPATHY PROLIFERATIVE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>VISUAL ACUITY REDUCED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>CHEILITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>ENTERITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>SUBMANDIBULAR MASS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>HAND-FOOT-AND-MOUTH DISEASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>HORDEOLUM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>OTITIS MEDIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>CONTUSION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>JOINT SPRAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>LIMB INJURY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>LOSS OF CONSCIOUSNESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>MYOCLONUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ADJUSTMENT DISORDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>MENSTRUATION IRREGULAR</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>PHARYNGOLARYNGEAL PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>TACHYPNOEA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ACNE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>ALOPECIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>ECZEMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>URTICARIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Shire‚Äôs agreements with investigators vary. All agreements provide Shire the right to embargo communications regarding trial results prior to public release for a period ‚â§180 days from the time submitted to Shire for review. Shire does not prohibit publication, but can require the removal of confidential information (excluding trial results) and can request postponement of a single-center publication until after disclosure of the trial‚Äôs multi-center publication</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>All 6 enrolled patients received previous long-term treatment with the enzyme replacement therapy (ERT), imiglucerase. Key therapeutic parameters were expected to indicate stability after switching from imiglucerase.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Bjorn Mellgard, MD, PhD</name_or_title>
      <organization>Shire</organization>
      <phone>+41 22 419 4110</phone>
      <email>bmellgard@shire.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

